Johnson & Johnson (NYSE:JNJ) Given New $210.00 Price Target at Rothschild & Co Redburn

Johnson & Johnson (NYSE:JNJ) had its price target hoisted by equities researchers at Rothschild & Co Redburn from $180.00 to $210.00 in a report issued on Thursday,MarketScreener reports. The brokerage currently has a “neutral” rating on the stock. Rothschild & Co Redburn’s price target indicates a potential downside of 14.40% from the company’s current price.

JNJ has been the subject of a number of other research reports. HSBC boosted their price objective on Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a report on Friday, January 30th. Wolfe Research increased their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research note on Monday, January 5th. The Goldman Sachs Group restated a “buy” rating and set a $250.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 22nd. Bank of America increased their price target on Johnson & Johnson from $220.00 to $221.00 and gave the stock a “neutral” rating in a research report on Thursday, January 22nd. Finally, Citigroup lifted their price objective on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $232.70.

Johnson & Johnson Trading Down 0.6%

Shares of JNJ traded down $1.59 during midday trading on Thursday, hitting $245.32. The stock had a trading volume of 952,842 shares, compared to its average volume of 9,161,753. The stock’s 50 day moving average is $220.45 and its 200 day moving average is $198.55. The firm has a market cap of $591.20 billion, a PE ratio of 22.20, a price-to-earnings-growth ratio of 2.38 and a beta of 0.35. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $246.96.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. This represents a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Johnson & Johnson

Institutional investors and hedge funds have recently modified their holdings of the company. Sierra Capital LLC raised its holdings in shares of Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after purchasing an additional 41 shares during the last quarter. Broadleaf Partners LLC raised its stake in shares of Johnson & Johnson by 0.6% during the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock valued at $1,521,000 after buying an additional 43 shares during the last quarter. Jessup Wealth Management Inc lifted its holdings in shares of Johnson & Johnson by 0.6% in the 4th quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock valued at $1,567,000 after buying an additional 44 shares during the period. Plancorp LLC raised its position in Johnson & Johnson by 0.3% during the fourth quarter. Plancorp LLC now owns 15,889 shares of the company’s stock valued at $3,288,000 after acquiring an additional 45 shares in the last quarter. Finally, Baron Silver Stevens Financial Advisors LLC lifted its holdings in Johnson & Johnson by 0.8% in the fourth quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,645 shares of the company’s stock valued at $1,168,000 after acquiring an additional 45 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Company is preparing a potential sale of its orthopedics unit that could fetch about $20 billion — investors may view a sale as value‑unlocking and a catalyst for multiple expansion if executed. Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports
• Positive Sentiment: Announced a >$1 billion investment in a Pennsylvania cell‑therapy manufacturing facility — expands U.S. capacity for high‑value biologics/cell therapies and supports long‑term revenue pipeline potential. Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
• Positive Sentiment: Strong early oncology data: investigational RYBREVANT FASPRO plus immunotherapy showed a 56% overall response rate in frontline recurrent/metastatic head & neck cancer — clinical upside that could boost future drug sales if confirmed. RYBREVANT FASPRO clinical results PR
• Positive Sentiment: Dividend/return focus highlighted in recent roundups — J&J remains a reliable dividend payer (recent quarterly payout noted), supporting income investor demand. Dividend Roundup: Halliburton, AbbVie, Johnson & Johnson, Delta Air Lines, and more
• Neutral Sentiment: Options and analyst attention have increased — can amplify near‑term moves but are not fundamental drivers by themselves. Monitor for large directional trades or fresh analyst revisions. Behind the Scenes of Johnson & Johnson’s Latest Options Trends
• Neutral Sentiment: Street coverage (Zacks, TipRanks) is keeping JNJ in focus — useful for sentiment but incremental to fundamental changes. Johnson & Johnson (JNJ) Is a Trending Stock
• Negative Sentiment: Insider selling: recent filings show EVP sales totaling millions of dollars (several thousand shares at ~$243–$244), which can be read negatively by some investors even if sales have benign explanations. Johnson & Johnson EVP Vanessa Broadhurst Sells 6,197 Shares
• Negative Sentiment: Ongoing talc litigation and renewed media focus on verdict risk continue to cloud valuation — legal overhang can limit multiple expansion and keeps headline risk elevated. Johnson & Johnson Balances Oncology Breakthrough With Rising Talc Litigation Risk

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.